DapaVilda 10/100SR

Introduction

The management of Type 2 diabetes requires a multifaceted approach, often involving a combination of medications that target different pathways to regulate blood sugar levels. DAPA VILDA 10/100 SR is a fixed-dose combination of Dapagliflozin (10mg) and Vildagliptin SR (100mg), which has proven to be an effective therapeutic option for individuals struggling to maintain optimal glucose control. This combination is designed to work synergistically, targeting multiple mechanisms that help reduce blood sugar levels and improve overall metabolic health.

In this article, we will provide an in-depth exploration of DAPA VILDA 10/100 SR, covering its key components, benefits, mechanisms of action, recommended dosage, potential side effects, and more.

Key Ingredients

1. Dapagliflozin (10mg)
   Dapagliflozin belongs to the class of medications known as SGLT2 inhibitors (Sodium-Glucose Cotransporter 2 inhibitors). These drugs work by blocking the SGLT2 protein in the kidneys, responsible for reabsorbing glucose back into the bloodstream. By inhibiting this protein, Dapagliflozin allows excess glucose to be excreted through the urine, thereby lowering blood sugar levels.

2. Vildagliptin SR (100mg)
   Vildagliptin is a DPP-4 inhibitor (Dipeptidyl Peptidase-4 inhibitor) that works by increasing the levels of incretin hormones, which stimulate insulin release in response to meals and inhibit glucagon secretion. By enhancing the action of these hormones, Vildagliptin helps improve blood sugar control, particularly after meals, and reduces the risk of excessive postprandial hyperglycemia.

How Does DAPA VILDA 10/100 SR Work?

The combination of Dapagliflozin (10mg) and Vildagliptin SR (100mg) works through complementary mechanisms that help achieve better glucose control in individuals with Type 2 diabetes:

1. Increased Glucose Excretion (Dapagliflozin)
   Dapagliflozin inhibits the SGLT2 protein in the kidneys, preventing glucose reabsorption. This results in increased glucose excretion through the urine, which lowers blood sugar levels. Additionally, by reducing glucose reabsorption, Dapagliflozin helps with weight management and may offer some cardiovascular protection.

2. Enhanced Insulin Secretion and Reduced Glucagon (Vildagliptin)
   Vildagliptin inhibits the DPP-4 enzyme, which is responsible for breaking down incretin hormones like GLP-1 and GIP. These hormones stimulate the pancreas to release insulin in response to meals, enhancing glucose uptake by the cells. Additionally, Vildagliptin suppresses the secretion of glucagon, a hormone that promotes glucose production by the liver. This dual action helps to improve both fasting and postprandial blood sugar levels.

3. Synergistic Effect
   By combining the effects of both drugs, DAPA VILDA 10/100 SR offers a comprehensive approach to managing blood sugar. The SGLT2 inhibition of Dapagliflozin works alongside the DPP-4 inhibition of Vildagliptin, creating a synergistic effect that targets multiple glucose-lowering pathways.

Benefits of DAPA VILDA 10/100 SR

1. Improved Glycemic Control
   The primary benefit of DAPA VILDA 10/100 SR is its ability to significantly lower blood glucose levels. By combining Dapagliflozin and Vildagliptin, it helps reduce both fasting and postprandial blood glucose levels, improving overall glycemic control in people with Type 2 diabetes.

2. Weight Loss
   One of the side effects of SGLT2 inhibitors like Dapagliflozin is weight loss. This is particularly beneficial for individuals with Type 2 diabetes, as many are also overweight or obese. The increased glucose excretion helps reduce body weight over time.

3. Cardiovascular Protection
   Recent studies have suggested that SGLT2 inhibitors may offer cardiovascular benefits by reducing the risk of heart failure and stroke. Additionally, by lowering blood glucose and blood pressure, DAPA VILDA 10/100 SR may help reduce the burden on the heart, especially in individuals with diabetes who are at a higher risk for cardiovascular diseases.

4. Convenient Dosing
   As a fixed-dose combination tablet, DAPA VILDA 10/100 SR simplifies the treatment regimen for patients. Patients who require both Dapagliflozin and Vildagliptin no longer need to take separate tablets, improving adherence to treatment.

5. Reduced Risk of Hypoglycemia
   Unlike some other diabetes medications, DAPA VILDA 10/100 SR does not significantly increase the risk of hypoglycemia (low blood sugar). This is particularly important for patients who are concerned about the risk of hypoglycemic episodes, which can be dangerous.

Recommended Dosage of DAPA VILDA 10/100 SR

The usual dose of DAPA VILDA 10/100 SR is one tablet taken once daily, preferably with or after a meal. It is important to follow the dosage instructions provided by a healthcare provider to ensure optimal results and minimize the risk of side effects.

Factors Affecting Dosage

• Renal Impairment: Since Dapagliflozin is eliminated by the kidneys, the dose may need to be adjusted for patients with renal impairment.
• Other Medications: Some medications, especially those that affect the renin-angiotensin system or are used to treat hypertension or heart disease, may interact with DAPA VILDA 10/100 SR, requiring dose adjustments.

Side Effects of DAPA VILDA 10/100 SR

Like all medications, DAPA VILDA 10/100 SR may cause side effects. However, not everyone will experience them. Common side effects include:

1. Urinary Tract Infections (UTIs)
   Dapagliflozin increases glucose excretion in the urine, which may promote the growth of bacteria, leading to a higher risk of UTIs. Patients should be vigilant about maintaining good hygiene and seeking medical attention if symptoms of a UTI arise.

2. Dehydration and Dizziness
   Since Dapagliflozin increases urine production, it may lead to dehydration, especially if patients are not drinking enough fluids. This can result in dizziness, lightheadedness, or fainting. Staying hydrated is crucial when using this medication.

3. Hypoglycemia
   Although DAPA VILDA 10/100 SR generally does not cause hypoglycemia on its own, when used in combination with other glucose-lowering medications like insulin or sulfonylureas, there is a potential risk of hypoglycemia. Patients should monitor their blood glucose levels regularly.

4. Gastrointestinal Issues
   Some patients may experience nausea, diarrhea, or abdominal discomfort when taking Vildagliptin. These symptoms typically subside after a few days, but if they persist, patients should consult their healthcare provider.

5. Allergic Reactions
   As with any medication, some individuals may experience allergic reactions such as skin rash, itching, or swelling. Severe reactions are rare but should be treated as a medical emergency if they occur.

6. Elevated LDL Cholesterol
   In some cases, Dapagliflozin has been associated with an increase in LDL cholesterol levels. While this does not appear to be clinically significant in most cases, patients with pre-existing high cholesterol may need to have their lipid levels monitored.

Precautions and Contraindications

1. Renal Impairment: DAPA VILDA 10/100 SR should be used cautiously in patients with moderate to severe renal impairment. In patients with end-stage renal disease or dialysis, the use of Dapagliflozin is contraindicated.

2. Liver Impairment: While Vildagliptin is generally well-tolerated, patients with severe liver disease should avoid this medication.

3. Pregnancy and Breastfeeding: The safety of DAPA VILDA 10/100 SR during pregnancy and breastfeeding has not been established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.

4. Dehydration and Electrolyte Imbalance: Care should be taken in patients who are prone to dehydration, as Dapagliflozin can cause increased urination and fluid loss. Patients should be advised to stay hydrated and avoid excessive alcohol consumption.

Conclusion

DAPA VILDA 10/100 SR is an effective combination therapy for managing Type 2 diabetes, offering both glycemic control and additional benefits such as weight loss and cardiovascular protection. By combining the actions of Dapagliflozin and Vildagliptin, this medication addresses multiple pathways involved in glucose metabolism.

However, like any medication, it is important to use DAPA VILDA 10/100 SR under the supervision of a healthcare provider, ensuring that the dosage is appropriate and that any potential side effects are monitored. Regular follow-ups and proper lifestyle management can further enhance the benefits of this medication and improve long-term diabetes management.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW